Celsentri

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

maraviroka

Available from:

ViiV Healthcare B.V.

ATC code:

J05AX09

INN (International Name):

maraviroc

Therapeutic group:

Antivirusni lijekovi za sustavnu uporabu

Therapeutic area:

HIV infekcije

Therapeutic indications:

Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable,.

Product summary:

Revision: 28

Authorization status:

odobren

Authorization date:

2007-09-18

Patient Information leaflet

                                93
B. UPUTA O LIJEKU
94
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
CELSENTRI 25 MG FILMOM OBLOŽENE TABLETE
CELSENTRI 75 MG FILMOM OBLOŽENE TABLETE
CELSENTRI 150 MG FILMOM OBLOŽENE TABLETE
CELSENTRI 300 MG FILMOM OBLOŽENE TABLETE
MARAVIROK
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
_ _
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je CELSENTRI i za što se koristi
2.
Što morate znati prije nego počnete uzimati CELSENTRI
3.
Kako uzimati CELSENTRI
4.
Moguće nuspojave
5.
Kako čuvati CELSENTRI
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE CELSENTRI I ZA ŠTO SE KORISTI
CELSENTRI sadrži lijek koji se zove maravirok. Maravirok pripada
skupini lijekova koji se nazivaju
_antagonistima CCR5_
. CELSENTRI djeluje tako da blokira receptor CCR5, koji HIV koristi
kako bi
ušao u krvne stanice i zarazio ih.
CELSENTRI SE KORISTI ZA LIJEČENJE INFEKCIJE VIRUSOM HUMANE
IMUNODEFICIJENCIJE TIPA 1 (HIV-1)
U ODRASLIH, ADOLESCENATA I DJECE U DOBI OD 2 ILI VIŠE GODINA I
TJELESNE TEŽINE OD NAJMANJE 10 KG.
CELSENTRI se mora primjenjivati u kombinaciji s drugim lijekovima koji
se također koriste za
liječenje HIV infekcije. Ti se lijekovi nazivaju
_lijekovima protiv HIV-a_
ili
_antiretroviroticima_
.
CELSENTRI, kao dio kombinirane terapije, smanjuje količinu virusa u
tijelu i održava razinu virusa
niskom. Na taj način pomaže tijelu da poveća broj CD4 stanica u
krvi. CD4 stanice su jedna vrsta
bijelih krvnih stanica koje su važne jer pomažu tijelu u borbi
protiv infekcije.
2.
ŠTO MORATE ZNATI PRIJE NEGO POČNETE U
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
CELSENTRI 25 mg filmom obložene tablete
CELSENTRI 75 mg filmom obložene tablete
CELSENTRI 150 mg filmom obložene tablete
CELSENTRI 300 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
CELSENTRI 25 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 25 mg maraviroka.
Pomoćna tvar s poznatim učinkom: jedna filmom obložena tableta od
25 mg sadrži 0,14 mg sojinog
lecitina.
CELSENTRI 75 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 75 mg maraviroka.
Pomoćna tvar s poznatim učinkom: jedna filmom obložena tableta od
75 mg sadrži 0,42 mg sojinog
lecitina.
CELSENTRI 150 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 150 mg maraviroka.
Pomoćna tvar s poznatim učinkom: jedna filmom obložena tableta od
150 mg sadrži 0,84 mg sojinog
lecitina.
CELSENTRI 300 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 300 mg maraviroka.
Pomoćna tvar s poznatim učinkom: jedna filmom obložena tableta od
300 mg sadrži 1,68 mg sojinog
lecitina.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta.
CELSENTRI 25 mg filmom obložene tablete
Plave, bikonveksne, ovalne filmom obložene tablete približnih
dimenzija 4,6 mm x 8,0 mm,
s utisnutom oznakom „MVC 25“.
CELSENTRI 75 mg filmom obložene tablete
Plave, bikonveksne, ovalne filmom obložene tablete približnih
dimenzija 6,74 mm x 12,2 mm,
s utisnutom oznakom „MVC 75“.
CELSENTRI 150 mg filmom obložene tablete
Plave, bikonveksne, ovalne filmom obložene tablete približnih
dimenzija 8,56 mm x 15,5 mm,
sutisnutom oznakom „MVC 150“.
3
CELSENTRI 300 mg filmom obložene tablete
Plave, bikonveksne, ovalne filmom obložene tablete približnih
dimenzija 10,5 mm x 19,0 mm,
s utisnutom oznakom „MVC 300“.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
CELSENTRI je u kombinaciji s drugim antiretrovirusnim lijekovima
indiciran u liječenju prethodno
liječenih odraslih osob
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 22-08-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 22-08-2022
Public Assessment Report Public Assessment Report Bulgarian 18-07-2017
Patient Information leaflet Patient Information leaflet Spanish 22-08-2022
Public Assessment Report Public Assessment Report Spanish 18-07-2017
Patient Information leaflet Patient Information leaflet Czech 22-08-2022
Public Assessment Report Public Assessment Report Czech 18-07-2017
Patient Information leaflet Patient Information leaflet Danish 22-08-2022
Public Assessment Report Public Assessment Report Danish 18-07-2017
Patient Information leaflet Patient Information leaflet German 22-08-2022
Public Assessment Report Public Assessment Report German 18-07-2017
Patient Information leaflet Patient Information leaflet Estonian 22-08-2022
Public Assessment Report Public Assessment Report Estonian 18-07-2017
Patient Information leaflet Patient Information leaflet Greek 22-08-2022
Public Assessment Report Public Assessment Report Greek 18-07-2017
Patient Information leaflet Patient Information leaflet English 22-08-2022
Public Assessment Report Public Assessment Report English 18-07-2017
Patient Information leaflet Patient Information leaflet French 22-08-2022
Public Assessment Report Public Assessment Report French 18-07-2017
Patient Information leaflet Patient Information leaflet Italian 22-08-2022
Public Assessment Report Public Assessment Report Italian 18-07-2017
Patient Information leaflet Patient Information leaflet Latvian 22-08-2022
Public Assessment Report Public Assessment Report Latvian 18-07-2017
Patient Information leaflet Patient Information leaflet Lithuanian 22-08-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 22-08-2022
Public Assessment Report Public Assessment Report Lithuanian 18-07-2017
Patient Information leaflet Patient Information leaflet Hungarian 22-08-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 22-08-2022
Public Assessment Report Public Assessment Report Hungarian 18-07-2017
Patient Information leaflet Patient Information leaflet Maltese 22-08-2022
Public Assessment Report Public Assessment Report Maltese 18-07-2017
Patient Information leaflet Patient Information leaflet Dutch 22-08-2022
Public Assessment Report Public Assessment Report Dutch 18-07-2017
Patient Information leaflet Patient Information leaflet Polish 22-08-2022
Public Assessment Report Public Assessment Report Polish 18-07-2017
Patient Information leaflet Patient Information leaflet Portuguese 22-08-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 22-08-2022
Public Assessment Report Public Assessment Report Portuguese 18-07-2017
Patient Information leaflet Patient Information leaflet Romanian 22-08-2022
Public Assessment Report Public Assessment Report Romanian 18-07-2017
Patient Information leaflet Patient Information leaflet Slovak 22-08-2022
Public Assessment Report Public Assessment Report Slovak 18-07-2017
Patient Information leaflet Patient Information leaflet Slovenian 22-08-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 22-08-2022
Public Assessment Report Public Assessment Report Slovenian 18-07-2017
Patient Information leaflet Patient Information leaflet Finnish 22-08-2022
Public Assessment Report Public Assessment Report Finnish 18-07-2017
Patient Information leaflet Patient Information leaflet Swedish 22-08-2022
Public Assessment Report Public Assessment Report Swedish 18-07-2017
Patient Information leaflet Patient Information leaflet Norwegian 22-08-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 22-08-2022
Patient Information leaflet Patient Information leaflet Icelandic 22-08-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 22-08-2022

Search alerts related to this product

View documents history